Abstract
Applicator shifts and DVH parameter changes induced the total dose inaccurately and could not be ignored. The doses of target volume and OARs varied inevitably.
Introduction
High-Dose-Rate (HDR) brachytherapy is a cornerstone of cervical cancer treatment, relying on 3D imaging for precise dose calculation. However, the dynamic nature of the human body and the time lag between imaging and treatment delivery can lead to physical shifts of the radiation applicator. This study, originally published in the Asian Pacific Journal of Cancer Prevention, quantifies these shifts using the Utrecht interstitial applicator and evaluates their impact on Dose-Volume Histogram (DVH) parameters for the tumor and surrounding organs at risk (OARs).
Methodology
The researchers evaluated 40 treatment fractions from 13 patients diagnosed with squamous cervical cancer. The clinical workflow involved the insertion of a Utrecht interstitial applicator followed by a planning CT scan. Target volumes (CTVhr) and OARs—including the bladder, rectum, sigmoid colon, and small intestines—were contoured by oncologists.
To assess positional stability, a second CT scan was performed immediately following the radiation treatment. These "before" and "after" scans were registered using stable pelvic bony structures. The displacement of the applicator's central tandem was measured at its tip and base across three spatial axes: X (lateral), Y (cranial-caudal), and Z (anterior-posterior). Finally, the radiation doses were recalculated based on the post-treatment applicator positions to determine the actual delivered dose.
Results
The study found that applicator shifts were not random but followed specific directional trends. The tandem consistently tended to shift toward the patient's head (cranial) and front (anterior). Average shifts in the Y-axis ranged from 1.49 mm to 2.14 mm, while Z-axis shifts ranged from 1.9 mm to 2.3 mm. Lateral (X-axis) movements were found to be negligible.
These mechanical displacements significantly altered the dose distribution. The dose to the high-risk clinical target volume (CTVhr D90) decreased by an average of 3.5%. While doses to the bladder, rectum, and sigmoid colon generally decreased as the applicator moved away from them, the dose to the small intestines increased significantly.
As shown in Figure 6, the biological equivalent dose (EQD2) to the small intestines (D2cc) increased by an average of 10.94%. This suggests that the cranial and anterior shifts of the applicator move the radiation source into closer proximity with the sensitive small bowel, potentially increasing the risk of complications.
Discussion and Conclusion
The results indicate that applicator shifts during HDR brachytherapy are inevitable and can compromise treatment accuracy. The observed reduction in tumor dose and the significant increase in small intestine exposure highlight the limitations of relying solely on a single pre-treatment planning scan.
The authors conclude that to ensure high-precision delivery, it is necessary to minimize the time between imaging and treatment or to perform a verification scan immediately before radiation delivery. Future research should investigate whether specific physiological factors, such as bladder or rectal filling, are the primary drivers of these applicator movements.
Summary updated